CSNK1G1

Summary

CSNK1G1 (casein kinase 1 gamma 1, HGNC:2454) is a protein-coding gene on chromosome 15q22.31, encoding Casein kinase I isoform gamma-1 (Q9HCP0). Serine/threonine-protein kinase.

This gene encodes a member of the casein kinase I gene family. This family is comprised of serine/threonine kinases that phosphorylate acidic proteins such as caseins. The encoded kinase plays a role in cell cycle checkpoint arrest in response to stalled replication forks by phosphorylating Claspin. A mutation in this gene may be associated with non-syndromic early-onset epilepsy (NSEOE).

Source: NCBI Gene 53944 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 13
• Clinical variants (ClinVar): 72 total — 1 likely-pathogenic
• Druggable target: yes — 22 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_022048

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2454
Approved symbol	CSNK1G1
Name	casein kinase 1 gamma 1
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	CK1gamma1
Ensembl gene	ENSG00000169118
Ensembl biotype	protein_coding
OMIM	606274
Entrez	53944

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 26 protein_coding, 3 nonsense_mediated_decay, 1 retained_intron

ENST00000303052, ENST00000561349, ENST00000606225, ENST00000606793, ENST00000607537, ENST00000634302, ENST00000634654, ENST00000634722, ENST00000634811, ENST00000634909, ENST00000635142, ENST00000635230, ENST00000635270, ENST00000635324, ENST00000635359, ENST00000635414, ENST00000635514, ENST00000635529, ENST00000887581, ENST00000887582, ENST00000887583, ENST00000887584, ENST00000919646, ENST00000919647, ENST00000919648, ENST00000947284, ENST00000947285, ENST00000947286, ENST00000947287, ENST00000947288

RefSeq mRNA: 4 — MANE Select: NM_022048 NM_001329605, NM_001329606, NM_001329607, NM_022048

CCDS: CCDS10192, CCDS86464, CCDS86465

Canonical transcript exons

ENST00000303052 — 12 exons

Exon	Start	End
ENSE00001259031	64165525	64171985
ENSE00002543634	64300319	64300723
ENSE00003468718	64204441	64204589
ENSE00003575858	64204865	64204949
ENSE00003584739	64180348	64180454
ENSE00003590303	64203082	64203189
ENSE00003617245	64207509	64207594
ENSE00003652782	64213890	64214124
ENSE00003697720	64355988	64356173
ENSE00003785020	64216562	64216713
ENSE00003785739	64251512	64251581
ENSE00003787357	64259201	64259241

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 96.33.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.6241 / max 86.6928, expressed in 1800 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150471	10.6327	1795
150470	0.9872	632
150469	0.0042	3

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	96.33	gold quality
esophagus squamous epithelium	UBERON:0006920	91.63	gold quality
left testis	UBERON:0004533	91.36	gold quality
right testis	UBERON:0004534	91.29	gold quality
testis	UBERON:0000473	89.87	gold quality
oocyte	CL:0000023	88.77	gold quality
bronchial epithelial cell	CL:0002328	87.57	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.27	gold quality
mucosa of paranasal sinus	UBERON:0005030	86.38	gold quality
sperm	CL:0000019	86.12	gold quality
corpus epididymis	UBERON:0004359	85.66	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.33	gold quality
calcaneal tendon	UBERON:0003701	84.99	gold quality
epithelium of esophagus	UBERON:0001976	84.75	gold quality
cortical plate	UBERON:0005343	84.43	gold quality
tendon of biceps brachii	UBERON:0008188	84.15	silver quality
tibia	UBERON:0000979	84.12	gold quality
tendon	UBERON:0000043	83.76	gold quality
mammary duct	UBERON:0001765	83.57	gold quality
male germ cell	CL:0000015	83.53	gold quality
oral cavity	UBERON:0000167	83.48	gold quality
palpebral conjunctiva	UBERON:0001812	82.92	gold quality
caput epididymis	UBERON:0004358	82.90	gold quality
adrenal tissue	UBERON:0018303	82.37	gold quality
visceral pleura	UBERON:0002401	81.57	gold quality
endometrium	UBERON:0001295	81.29	gold quality
middle temporal gyrus	UBERON:0002771	80.93	gold quality
islet of Langerhans	UBERON:0000006	80.86	gold quality
parietal pleura	UBERON:0002400	80.71	gold quality
tonsil	UBERON:0002372	80.62	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

253 targeting CSNK1G1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593

Literature-anchored findings (GeneRIF, showing 3)

• A 1756 bp cDNA encoded human protein kinase CK1 (438 AA, mol wt 50.272 Da, isoelectric point of 9.37) mapping to chromosome 15q22. (PMID:12119564)
• casein kinase 1 gamma 1 phosphorylates claspin (PMID:21680713)
• CK1gamma1 phosphorylates p65 and consequently promotes its degradation by ubiquitin E3 ligases CUL2 and COMMD1. (PMID:24442433)

Cross-species orthologs

68 orthologs

Organism	Symbol	Gene ID
danio_rerio	csnk1g1	ENSDARG00000104342
mus_musculus	Csnk1g1	ENSMUSG00000032384
rattus_norvegicus	Csnk1g1	ENSRNOG00000016620
drosophila_melanogaster	ball	FBGN0027889
drosophila_melanogaster	CG9962	FBGN0031441
caenorhabditis_elegans		WBGENE00007049
caenorhabditis_elegans		WBGENE00007269
caenorhabditis_elegans		WBGENE00007305
caenorhabditis_elegans		WBGENE00007335
caenorhabditis_elegans		WBGENE00007448
caenorhabditis_elegans		WBGENE00007777
caenorhabditis_elegans		WBGENE00007791
caenorhabditis_elegans		WBGENE00008088
caenorhabditis_elegans		WBGENE00008423
caenorhabditis_elegans		WBGENE00008464
caenorhabditis_elegans	F10G8.2	WBGENE00008662
caenorhabditis_elegans		WBGENE00008883
caenorhabditis_elegans		WBGENE00009324
caenorhabditis_elegans		WBGENE00009402
caenorhabditis_elegans		WBGENE00010555
caenorhabditis_elegans		WBGENE00010692
caenorhabditis_elegans		WBGENE00010874
caenorhabditis_elegans		WBGENE00011283
caenorhabditis_elegans		WBGENE00012169
caenorhabditis_elegans		WBGENE00012637
caenorhabditis_elegans		WBGENE00012731
caenorhabditis_elegans		WBGENE00013868
caenorhabditis_elegans		WBGENE00014007
caenorhabditis_elegans		WBGENE00015893
caenorhabditis_elegans		WBGENE00016111
caenorhabditis_elegans	C34B2.3	WBGENE00016388
caenorhabditis_elegans		WBGENE00016513
caenorhabditis_elegans		WBGENE00016541
caenorhabditis_elegans		WBGENE00016673
caenorhabditis_elegans		WBGENE00016765
caenorhabditis_elegans	C55B7.10	WBGENE00016946
caenorhabditis_elegans		WBGENE00016963
caenorhabditis_elegans		WBGENE00017050
caenorhabditis_elegans		WBGENE00017714
caenorhabditis_elegans		WBGENE00017725
caenorhabditis_elegans		WBGENE00017803
caenorhabditis_elegans		WBGENE00017895
caenorhabditis_elegans	F33D11.7	WBGENE00018004
caenorhabditis_elegans		WBGENE00018122
caenorhabditis_elegans		WBGENE00018123
caenorhabditis_elegans		WBGENE00018202
caenorhabditis_elegans		WBGENE00018203
caenorhabditis_elegans		WBGENE00018745
caenorhabditis_elegans		WBGENE00018839
caenorhabditis_elegans		WBGENE00019086
caenorhabditis_elegans		WBGENE00019119
caenorhabditis_elegans		WBGENE00019459
caenorhabditis_elegans		WBGENE00019556
caenorhabditis_elegans		WBGENE00019561
caenorhabditis_elegans		WBGENE00019562
caenorhabditis_elegans		WBGENE00019642
caenorhabditis_elegans	kin-35	WBGENE00019769
caenorhabditis_elegans		WBGENE00020071
caenorhabditis_elegans		WBGENE00020072
caenorhabditis_elegans		WBGENE00020223
caenorhabditis_elegans		WBGENE00020580
caenorhabditis_elegans	W09C3.1	WBGENE00021109
caenorhabditis_elegans	Y47G6A.13	WBGENE00021639
caenorhabditis_elegans	Y65B4A.9	WBGENE00022032
caenorhabditis_elegans		WBGENE00022102
caenorhabditis_elegans	Y71F9AL.2	WBGENE00022108
caenorhabditis_elegans		WBGENE00022705
caenorhabditis_elegans		WBGENE00022707

Paralogs (12): VRK2 (ENSG00000028116), CDC7 (ENSG00000097046), VRK1 (ENSG00000100749), VRK3 (ENSG00000105053), CSNK1A1 (ENSG00000113712), TTBK2 (ENSG00000128881), CSNK1G2 (ENSG00000133275), CSNK1D (ENSG00000141551), TTBK1 (ENSG00000146216), CSNK1G3 (ENSG00000151292), CSNK1A1L (ENSG00000180138), CSNK1E (ENSG00000213923)

Protein

Protein identifiers

Casein kinase I isoform gamma-1 — Q9HCP0 (reviewed: Q9HCP0)

All UniProt accessions (15): Q9HCP0, A0A0U1RQG9, A0A0U1RQH9, A0A0U1RQK2, A0A0U1RQK6, A0A0U1RQN5, A0A0U1RQT7, A0A0U1RQU4, A0A0U1RQY7, A0A0U1RR14, A0A0U1RR31, A0A0U1RRH5, Q8IXA3, U3KQA5, U3KQB3

UniProt curated annotations — full annotation on UniProt →

Function. Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate. Phosphorylates CLSPN.

Subunit / interactions. Monomer.

Subcellular location. Cytoplasm.

Post-translational modifications. Autophosphorylated.

Activity regulation. Repressed by 2-(2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine (DB08325).

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the protein kinase superfamily. CK1 Ser/Thr protein kinase family. Casein kinase I subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HCP0-1	1L	yes
Q9HCP0-2	1S

RefSeq proteins (4): NP_001316534, NP_001316535, NP_001316536, NP_071331* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR022247	Casein_kinase-1_gamma_C	Domain
IPR050235	CK1_Ser-Thr_kinase-like	Family

Pfam: PF00069, PF12605

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (41 total): helix 10, turn 8, strand 7, sequence variant 3, compositionally biased region 3, region of interest 2, binding site 2, chain 1, domain 1, modified residue 1, splice variant 1, mutagenesis site 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2CMW	X-RAY DIFFRACTION	1.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCP0-F1	79.53	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 164 (proton acceptor)

Ligand- & substrate-binding residues (2): 50–58; 73

Post-translational modifications (1): 344

Mutagenesis-validated functional residues (1):

Position	Phenotype
169	loss of kinase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 178 (showing top): AGGAAGC_MIR5163P, KEGG_HEDGEHOG_SIGNALING_PATHWAY, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, TGCACTT_MIR519C_MIR519B_MIR519A, ATACCTC_MIR202, AAGCCAT_MIR135A_MIR135B, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, CCTGTGA_MIR513, GRE_C, PID_FOXO_PATHWAY, OCT1_07, TTGGAGA_MIR5155P_MIR519E

GO Biological Process (5): endocytosis (GO:0006897), signal transduction (GO:0007165), Wnt signaling pathway (GO:0016055), positive regulation of canonical Wnt signaling pathway (GO:0090263), protein phosphorylation (GO:0006468)

GO Molecular Function (8): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein kinase activity	2
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cell surface receptor signaling pathway	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
phosphorylation	1
protein modification process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1052 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSNK1G1	LRP6	O75581	627
CSNK1G1	AXIN1	O15169	567
CSNK1G1	STK16	O75716	467
CSNK1G1	CTNNB1	P35222	441
CSNK1G1	WNT2	P09544	423
CSNK1G1	MLKL	Q8NB16	421
CSNK1G1	LRP8	Q14114	420
CSNK1G1	PPM1B	O75688	418
CSNK1G1	CSNK2B	P07312	394
CSNK1G1	CSNK1G3	Q9Y6M4	390
CSNK1G1	CSNK1G2	P78368	388
CSNK1G1	PIGQ	Q9BRB3	363
CSNK1G1	N0E472	N0E472	358
CSNK1G1	GTF2I	P78347	357
CSNK1G1	OAZ2	O95190	357

IntAct

36 interactions, top by confidence:

A	B	Type	Score
CSNK1G1	CSNK1G2	psi-mi:“MI:0915”(physical association)	0.670
EFNB3	DENND11	psi-mi:“MI:0914”(association)	0.640
CSNK1G1	CSNK1G3	psi-mi:“MI:0915”(physical association)	0.620
CSNK1G1	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.560
CSNK1G1	CEP76	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-7	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.560
CEP76	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.560
TMEM185A	TSPAN6	psi-mi:“MI:0914”(association)	0.530
CIMAP3	PSMG3	psi-mi:“MI:0914”(association)	0.530
CD53	FAM171A2	psi-mi:“MI:0914”(association)	0.530
CSNK1G2	MAPK14	psi-mi:“MI:0914”(association)	0.530
LRRK2	CSNK1G1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400
GPC1	GANAB	psi-mi:“MI:0915”(physical association)	0.400
CSNK1G1	AMMECR1	psi-mi:“MI:0915”(physical association)	0.400
CSNK1G1	WDCP	psi-mi:“MI:0915”(physical association)	0.370
FAM219A	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.370
IKZF1	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.370
CSNK1G1	MKRN1	psi-mi:“MI:0915”(physical association)	0.370
RUNDC3B	CSNK1G1	psi-mi:“MI:0915”(physical association)	0.370
	SGK1	psi-mi:“MI:0914”(association)	0.350
	PAK4	psi-mi:“MI:0914”(association)	0.350
CSNK1G2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
HASPIN	MYO1C	psi-mi:“MI:0914”(association)	0.350
CSNK1G1	GNAI3	psi-mi:“MI:0914”(association)	0.350
TPX2	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.350
RNF149	CCDC85C	psi-mi:“MI:0914”(association)	0.350
BTNL9	GPR89A	psi-mi:“MI:0914”(association)	0.350

BioGRID (58): CEP76 (Two-hybrid), KRTAP10-7 (Two-hybrid), CSNK1G1 (Affinity Capture-MS), CSNK1G2 (Affinity Capture-MS), CSNK1G1 (Reconstituted Complex), CSNK1G1 (Affinity Capture-MS), CSNK1G2 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-RNA), CSNK1G1 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS), CSNK1G1 (Affinity Capture-MS)

ESM2 similar proteins: A7E3X2, O74135, P29295, P35508, P40233, P40234, P40236, P42158, P48730, P49674, P51566, P78368, Q03141, Q06486, Q20471, Q39050, Q4R9A9, Q556Y4, Q5BP74, Q5PRD4, Q5R4V3, Q5RC72, Q5XF24, Q5ZJS0, Q5ZLL1, Q62761, Q62762, Q62763, Q6K9N1, Q6NRT0, Q6P3K7, Q6P647, Q7T2E3, Q8BTH8, Q8BVP5, Q8C4X2, Q8LPI7, Q8LPJ1, Q8VYK9, Q8WQ99

Diamond homologs: A7E3X2, B9VVJ6, O15726, O19175, O74135, O76324, O80888, P16912, P22517, P23291, P23292, P28327, P29295, P34516, P34633, P35507, P35508, P35509, P39962, P40230, P40233, P40234, P40235, P40236, P42158, P42168, P48729, P48730, P49615, P49674, P51166, P54367, P67827, P67828, P67829, P67962, P67963, P78368, P81123, P97633

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
CSNK1G1	up-regulates	LRP6	phosphorylation
AMER1	up-regulates	CSNK1G1	binding
CSNK1G1	“up-regulates quantity by stabilization”	LYN	phosphorylation
CSNK1G1	“down-regulates activity”	FOXO1	phosphorylation
CSNK1G1	“down-regulates activity”	FOXO	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	48
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3776245	NM_022048.5(CSNK1G1):c.932dup (p.Thr312fs)	Likely pathogenic

SpliceAI

2959 predictions. Top by Δscore:

Variant	Effect	Δscore
15:64171853:T:TA	donor_gain	1.0000
15:64180346:A:AC	donor_gain	1.0000
15:64180347:C:CT	donor_gain	1.0000
15:64180347:CTTAG:C	donor_gain	1.0000
15:64180350:AG:A	donor_gain	1.0000
15:64180350:AGCTT:A	donor_gain	1.0000
15:64180351:G:C	donor_gain	1.0000
15:64180354:T:TA	donor_gain	1.0000
15:64180366:TCC:T	donor_gain	1.0000
15:64180455:C:CG	acceptor_loss	1.0000
15:64203185:GTAGG:G	acceptor_gain	1.0000
15:64203186:TAGG:T	acceptor_gain	1.0000
15:64203187:AGG:A	acceptor_gain	1.0000
15:64203188:GG:G	acceptor_gain	1.0000
15:64203188:GGCT:G	acceptor_loss	1.0000
15:64203190:C:CC	acceptor_gain	1.0000
15:64203190:C:CG	acceptor_loss	1.0000
15:64203191:T:C	acceptor_loss	1.0000
15:64204435:A:AC	donor_gain	1.0000
15:64204436:C:CC	donor_gain	1.0000
15:64204437:TTAC:T	donor_loss	1.0000
15:64204438:TA:T	donor_loss	1.0000
15:64204439:A:AC	donor_gain	1.0000
15:64204439:ACA:A	donor_loss	1.0000
15:64204440:C:A	donor_loss	1.0000
15:64204440:C:CT	donor_gain	1.0000
15:64204440:CA:C	donor_gain	1.0000
15:64204440:CAA:C	donor_gain	1.0000
15:64204440:CAAT:C	donor_gain	1.0000
15:64204440:CAATA:C	donor_gain	1.0000

AlphaMissense

2766 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:64204456:C:A	W328C	1.000
15:64204456:C:G	W328C	1.000
15:64204458:A:G	W328R	1.000
15:64204458:A:T	W328R	1.000
15:64204535:G:T	P302H	1.000
15:64204546:G:C	F298L	1.000
15:64204546:G:T	F298L	1.000
15:64204547:A:G	F298S	1.000
15:64204548:A:G	F298L	1.000
15:64204553:A:G	L296P	1.000
15:64204559:C:A	R294M	1.000
15:64204571:A:G	L290P	1.000
15:64204575:A:C	Y289D	1.000
15:64204905:T:A	K270N	1.000
15:64204905:T:G	K270N	1.000
15:64204906:T:A	K270I	1.000
15:64204906:T:G	K270T	1.000
15:64204907:T:C	K270E	1.000
15:64204907:T:G	K270Q	1.000
15:64204915:C:T	G267D	1.000
15:64204918:A:C	I266S	1.000
15:64204918:A:T	I266N	1.000
15:64204927:T:C	Y263C	1.000
15:64204928:A:C	Y263D	1.000
15:64204928:A:G	Y263H	1.000
15:64204929:T:A	R262S	1.000
15:64204929:T:G	R262S	1.000
15:64204930:C:A	R262I	1.000
15:64204930:C:G	R262T	1.000
15:64207513:A:G	L254P	1.000

dbSNP variants (sampled 300 via entrez): RS1000006440 (15:64289440 T>G), RS1000058010 (15:64221867 G>C,T), RS1000074630 (15:64306052 T>C,G), RS1000083322 (15:64277075 T>C), RS1000087779 (15:64171250 GTT>G,GTTT), RS1000115771 (15:64279826 G>T), RS1000120251 (15:64179237 C>A), RS1000121875 (15:64264765 C>G), RS1000126446 (15:64306342 G>A), RS1000126646 (15:64298356 T>C), RS1000127787 (15:64190112 G>A), RS1000176846 (15:64275677 T>C), RS1000189831 (15:64208765 G>A), RS1000208805 (15:64316209 A>G), RS1000228079 (15:64240051 T>C)

Disease associations

OMIM: gene MIM:606274 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (2): neurodevelopmental disorder (MONDO:0700092), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST004609_214	Monocyte percentage of white cells	2.000000e-11
GCST004625_151	Monocyte count	8.000000e-25
GCST004626_133	Myeloid white cell count	3.000000e-12
GCST005232_36	Neuroticism	3.000000e-07
GCST007709_133	General factor of neuroticism	3.000000e-08
GCST007824_9	Monoclonal gammopathy of undetermined significance	6.000000e-06
GCST90002379_68	Basophil count	9.000000e-14
GCST90002390_415	Mean corpuscular hemoglobin	3.000000e-12
GCST90002392_428	Mean corpuscular volume	2.000000e-15
GCST90002393_606	Monocyte count	3.000000e-65
GCST90002394_492	Monocyte percentage of white cells	2.000000e-31
GCST90002397_259	Mean spheric corpuscular volume	1.000000e-15
GCST90002407_592	White blood cell count	7.000000e-24

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0007989	monocyte percentage of leukocytes
EFO:0005091	monocyte count
EFO:0007660	neuroticism measurement
EFO:0005090	basophil count
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2111458 (PROTEIN FAMILY), CHEMBL2426 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

22 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 150,289 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL2105759	BARICITINIB	4	6,741
CHEMBL535	SUNITINIB	4	79,020
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL1230165	SILMITASERTIB	2	593
CHEMBL14762	SELICICLIB	2	3,787
CHEMBL1614713	CC-401	2	389
CHEMBL1721885	SU-014813	2	363
CHEMBL1967878	CENISERTIB	2	358
CHEMBL1980297	ILORASERTIB	2	581
CHEMBL230011	TG100-115	2	1,504
CHEMBL363648	TAK-715	2	442
CHEMBL4462530	ZEMIRCICLIB	2	429
CHEMBL513909	BI-2536	2	895
CHEMBL1084546	PF-00562271	1	399
CHEMBL1908397	KW-2449	1	622
CHEMBL3544966	GSK-1059615	1	1,928
CHEMBL3545083	RGB-286638	1	551
CHEMBL412142	LADUVIGLUSIB	1	8,434
CHEMBL482967	CYC-116	1
CHEMBL574738	AST-487	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Casein kinase 1 (CK1) family

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
voruciclib	Inhibition	6.96	pIC50
compound 33 [PMID: 19364658]	Inhibition	6.8	pIC50
SGC-CK1γ-1	Inhibition	6.74	pIC50

Binding affinities (BindingDB)

3 measured of 3 human assays (3 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

250 potent at pChembl≥5 of 262 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.40	IC50	4	nM	SILMITASERTIB
8.40	Ki	3.981	nM	CHEMBL371206
7.90	Ki	12.59	nM	CHEMBL2003638
7.80	Ki	15.85	nM	CHEMBL1969588
7.80	Ki	15.85	nM	CHEMBL1999931
7.70	Ki	19.95	nM	CHEMBL1997340
7.70	Ki	19.95	nM	CHEMBL2003271
7.70	Ki	19.95	nM	CHEMBL1986139
7.70	Ki	19.95	nM	CHEMBL1967531
7.70	Ki	19.95	nM	CHEMBL1973893
7.70	Ki	19.95	nM	CHEMBL1984586
7.70	Ki	19.95	nM	CHEMBL2006785
7.70	Ki	19.95	nM	CHEMBL2005828
7.70	Ki	19.95	nM	CHEMBL1973098
7.60	Ki	25.12	nM	CHEMBL1991078
7.60	Ki	25.12	nM	CHEMBL1965660
7.50	Ki	31.62	nM	CHEMBL1996066
7.46	IC50	35	nM	HYMENIALDISINE
7.40	Ki	39.81	nM	CHEMBL1970903
7.40	Ki	39.81	nM	CHEMBL1972937
7.40	Ki	39.81	nM	CHEMBL1999714
7.30	Ki	50.12	nM	CHEMBL1981079
7.28	Kd	53	nM	CYC-116
7.23	Kd	59	nM	CHEMBL526901
7.20	Ki	63.1	nM	CHEMBL1994830
7.20	Ki	63.1	nM	CHEMBL1998159
7.10	Ki	79.43	nM	CHEMBL1974870
7.10	Ki	79.43	nM	CHEMBL1964290
7.10	Ki	79.43	nM	CHEMBL1989646
7.00	Ki	100	nM	CHEMBL396523
7.00	Ki	100	nM	CHEMBL1966628
6.90	Ki	125.9	nM	CHEMBL2006439
6.90	Ki	125.9	nM	CHEMBL1991063
6.80	IC50	160	nM	CHEMBL511410
6.80	Ki	158.5	nM	CHEMBL1994864
6.80	Ki	158.5	nM	CENISERTIB
6.80	Ki	158.5	nM	CHEMBL1992937
6.80	Ki	158.5	nM	CHEMBL243088
6.80	Ki	158.5	nM	CHEMBL1975900
6.64	IC50	230	nM	CHEMBL5091216
6.63	Kd	234	nM	CHEMBL3752910
6.60	IC50	250	nM	CHEMBL466496
6.60	Ki	251.2	nM	CHEMBL1964692
6.60	Ki	251.2	nM	CHEMBL1965836
6.60	Ki	251.2	nM	CHEMBL1988153
6.60	Ki	251.2	nM	CHEMBL226403
6.60	Ki	251.2	nM	CHEMBL1975208
6.60	Ki	251.2	nM	CHEMBL225519
6.57	ED50	270.4	nM	CHEMBL3752910
6.55	Kd	282	nM	CC-401

PubChem BioAssay actives

52 with measured affinity, of 1785 total; 43 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid	1831537: Inhibition of CK1 (unknown origin)	ic50	0.0040	uM
(4Z)-4-(2-amino-5-oxo-1H-imidazol-4-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one	1924344: Inhibition of CK1 (unknown origin)	ic50	0.0350	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0530	uM
1-(4-methyl-2,5-dipyridin-4-yl-1H-pyrrol-3-yl)ethanone	389088: Binding affinity to human CK1gamma1	kd	0.0590	uM
2-[[3,4-dioxo-2-(pyridin-4-ylamino)cyclobuten-1-yl]amino]-2-(3-hydroxyphenyl)acetamide	351125: Inhibition of CK1-gamma1	ic50	0.1600	uM
N-[3-chloro-4-(4-methylpiperazin-1-yl)phenyl]-2-[4-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)phenoxy]acetamide	1831537: Inhibition of CK1 (unknown origin)	ic50	0.2300	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148160: Binding affinity to human CSNK1G1 incubated for 45 mins by Kinobead based pull down assay	kd	0.2340	uM
3-[[(1R)-1-phenylethyl]amino]-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione	351125: Inhibition of CK1-gamma1	ic50	0.2500	uM
3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2820	uM
4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide	1539768: Inhibition of human CK1 in presence of [gamma33P]-ATP	ic50	0.3000	uM
2-[[3,4-dioxo-2-(pyridin-4-ylamino)cyclobuten-1-yl]amino]-2-phenylacetamide	351125: Inhibition of CK1-gamma1	ic50	0.5200	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	625128: Binding constant for CSNK1G1 kinase domain	kd	0.5300	uM
4-[[5-amino-1-(3-methylthiophene-2-carbonyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	240570: Inhibition of casein kinase-1	ic50	0.5700	uM
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.6650	uM
Ruxolitinib	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.8510	uM
Sunitinib	435397: Binding constant for CSNK1G1 kinase domain	kd	0.9300	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435397: Binding constant for CSNK1G1 kinase domain	kd	1.0000	uM
3-(2-aminopyrimidin-4-yl)-6-bromo-1H-indol-4-ol	49209: Inhibition of Casein kinase I (CK1)	ic50	1.0000	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	625128: Binding constant for CSNK1G1 kinase domain	kd	1.0000	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625128: Binding constant for CSNK1G1 kinase domain	kd	1.2000	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	625128: Binding constant for CSNK1G1 kinase domain	kd	1.2000	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435397: Binding constant for CSNK1G1 kinase domain	kd	1.2000	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	49334: Inhibition of Casein kinase I	ic50	1.4000	uM
Baricitinib	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.7530	uM
5-amino-N-(2,6-difluorophenyl)-3-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide	240570: Inhibition of casein kinase-1	ic50	2.8000	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148160: Binding affinity to human CSNK1G1 incubated for 45 mins by Kinobead based pull down assay	kd	2.9496	uM
3-[[4-[4-(3-chloroanilino)-1,3,5-triazin-2-yl]-2-pyridinyl]amino]propan-1-ol	240612: Inhibition of Casein kinase I	ic50	3.0500	uM
1-[3-[4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-4-oxo-1H-indeno[2,1-d]pyrazol-5-yl]-3-morpholin-4-ylurea	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.1800	uM
(2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol	256655: Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM	kd	3.3000	uM
14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one	256655: Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM	kd	3.7000	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	625128: Binding constant for CSNK1G1 kinase domain	kd	3.9000	uM
(5Z)-5-(2-bromo-8-oxo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-4-ylidene)imidazolidine-2,4-dione	1924344: Inhibition of CK1 (unknown origin)	ic50	4.5000	uM
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	625128: Binding constant for CSNK1G1 kinase domain	kd	4.5000	uM
3-[[2-(furan-2-yl)-4-pyridinyl]amino]-4-[[(1R)-1-phenylethyl]amino]cyclobut-3-ene-1,2-dione	351125: Inhibition of CK1-gamma1	ic50	4.9000	uM
cis-(1S,3R)-3-acetamido-N-[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[2,1-e]pyrazol-3-yl)-2-pyridinyl]cyclohexane-1-carboxamide	1684217: Inhibition of CK1gamma1 (unknown origin) in presence of 5 mM ATP	ic50	5.5200	uM
N-(3-chlorophenyl)-6-[5-(3-pyrazol-1-ylpropylamino)-3-pyridinyl]pyrazin-2-amine	240683: Inhibition of casein kinase 1	ic50	5.6000	uM
3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol	625128: Binding constant for CSNK1G1 kinase domain	kd	5.7000	uM
N-(3-chlorophenyl)-6-[5-[3-(1,2,4-triazol-1-yl)propylamino]-3-pyridinyl]pyrazin-2-amine	240683: Inhibition of casein kinase 1	ic50	6.5000	uM
N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[2,1-d]pyrazol-3-amine	256725: Inhibitory activity against Casein Kinase 1	ic50	7.2000	uM
N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide	1539765: Inhibition of CK1 (unknown origin)	ic50	9.5000	uM
3-[7-[4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl]phenol	469352: Inhibition of CK1gamma1	ic50	9.5100	uM
5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-tert-butylpyridine-3-sulfonamide	713437: Inhibition of CSNK1G1	ic50	9.5499	uM
(5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione	1424964: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	17.4630	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression, increases methylation	2
Formaldehyde	decreases expression, increases expression	2
triphenyl phosphate	affects expression	1
sodium arsenite	decreases expression	1
cupric chloride	decreases expression	1
beta-methylcholine	affects expression	1
3,4,5,4’-tetramethoxystilbene	affects expression	1
torcetrapib	increases expression	1
bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Atrazine	decreases expression	1
Cisplatin	increases expression	1
Coumestrol	affects cotreatment, increases expression, decreases expression	1
Demecolcine	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Rifampin	decreases expression	1
Testosterone	decreases expression	1
Dronabinol	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	affects expression	1
Tunicamycin	increases expression	1
Urethane	increases expression	1
Vincristine	increases expression	1

ChEMBL screening assays

297 unique, capped per target: 296 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1051274	Binding	Percent residual CK1 activity in the presence of 10uM inhibitor	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). — Biochem J
CHEMBL1963743	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK1G1	PubChem BioAssay data set

Cellosaurus cell lines

8 cell lines: 7 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1PG	Abcam HeLa CSNK1G1 KO	Cancer cell line	Female
CVCL_D7MY	Ubigene A-549 CSNK1G1 KO	Cancer cell line	Male
CVCL_D8JF	Ubigene HCT 116 CSNK1G1 KO	Cancer cell line	Male
CVCL_D9CG	Ubigene HEK293 CSNK1G1 KO	Transformed cell line	Female
CVCL_E0B5	Ubigene HeLa CSNK1G1 KO	Cancer cell line	Female
CVCL_SJ84	HAP1 CSNK1G1 (-) 1	Cancer cell line	Male
CVCL_SJ85	HAP1 CSNK1G1 (-) 2	Cancer cell line	Male
CVCL_SJ86	HAP1 CSNK1G1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

204 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism